ArticleNPJ precision oncology2025
Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma.
Dimity Ball et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it